Clinical outcomes in patients with stage non-seminomatous germ cell cancer
Clinical outcomes in patients with stage non-seminomatous germ cell cancer作者机构：Shenzhen Second People's Hospital the First Affiliated Hospital of Shenzhen University Shenzhen 518036 China LAnhui Medical University Hefei 230032 China Department of Urology Sun Yat-Sen University Cancer Centre Guangzhou 510060 China Institute of Immunology Zhongshan School of Medicine Sun Yat-Sen University Guangzhou 510060 China and Institute of Urology Shenzhen PKU-HKUST Medical Centre Shenzhen 518036 China
出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)
年 卷 期：2013年第15卷第4期
页 面：558-563,I0011页
核心收录：
学科分类：0710[理学-生物学] 07[理学] 0905[农学-畜牧学] 08[工学] 09[农学] 071007[理学-遗传学] 0901[农学-作物学] 090501[农学-动物遗传育种与繁殖] 0836[工学-生物工程] 090102[农学-作物遗传育种]
基 金：supported by grants from the Chinese High Tech (863) Program 国家自然科学基金
主 题：chemotherapy clinical stage I non-seminomatous germ cell testicular cancer (CSI NSGCT) outcome retroperitoneallymph node dissection (RPLND) surveillance treatment protocols
摘 要：This study assesses the long-term outcomes in Han Chinese patients with clinical stage I non-seminomatous germ cell testicular cancer （CSI NSGCT） treated with surveillance, retroperitoneal lymph node dissection （RPLND） and adjuvant chemotherapy. We retrospectively evaluated 89 patients with a mean age of 26.5 years. After orchiectomy, 37 patients were treated with surveillance, 34 underwent RPLND and 18 were managed with chemotherapy. The overall survival rate, the recurrence-free survival rate and the risk factors were evaluated. The median follow-up length was 92 months （range： 6-149 months）. Thirteen of the 89 patients （14.6%） had relapses, and one died by the evaluation date. The overall survival rate was 98.9%. The cumulative 4-year recurrence-free rates were 80.2%, 92.0% and 100% for the surveillance, RPLND and chemotherapy groups, respectively. The disease-free period tended to be briefer in patients with a history of cryptorchidism and those with stage Is. Therefore, surveillance, RPLND and adjuvant chemotherapy might be reliable strategies in compliant patients with CSI NSGCT. Surveillance should be recommended for patients with the lowest recurrence rate, especially those without lymphovascular invasion. This study might aid the establishment of a standard therapy for CSI NSGCT in China.
维普期刊数据库